We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ALZN Alzamend Neuro Inc

-0.02 (-1.8%)
Dec 08 2023 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -1.8% 1.09 18:32:44
Open Price Low Price High Price Close Price Prev Close
1.11 1.03 1.1101 1.07 1.11
more quote information »

Recent News

Date Time Source Heading
11/20/202308:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
11/16/202316:30EDGAR2Form 8-K - Current report
11/16/202308:00BWAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
11/13/202308:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
10/30/202316:30EDGAR2Form 8-K - Current report
10/30/202308:00BWAlzamend Neuro Announces Reverse Stock Split
10/23/202308:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
10/02/202308:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
9/29/202316:30EDGAR2Form 8-K - Current report
9/26/202318:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/22/202316:30EDGAR2Form 8-K - Current report
9/22/202308:00BWAlzamend Neuro Granted Extension by Nasdaq Panel to Regain..
9/13/202317:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
9/08/202317:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
9/08/202317:00EDGAR2Form 8-K - Current report
9/01/202316:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
8/30/202308:00BWAlzamend Neuro Submits IND Application for Phase IIA..
8/24/202316:30EDGAR2Form DEF 14A - Other definitive proxy statements
8/16/202316:30EDGAR2Form 8-K - Current report
8/11/202300:15EDGAR2Form EFFECT - Notice of Effectiveness
8/10/202316:30EDGAR2Form PRE 14A - Other preliminary proxy statements
8/07/202316:30EDGAR2Form 8-K - Current report
8/02/202316:31EDGAR2Form S-3 - Registration statement under Securities Act of..
7/27/202316:56EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
6/22/202308:00BWAlzamend Neuro Announces Positive Phase IIA Clinical Trial..
6/13/202308:00BWAlzamend Neuro CEO Stephan Jackman to Participate on the..
4/04/202306:30BWAult Alliance Announces Alzamend Neuro Has Initiated Its..
4/03/202309:35BWKILL Alzamend Neuro Receives FDA “Study May Proceed” Letter..
4/03/202308:50BWAlzamend Neuro Announces the Initiation of a Phase I/IIA..
4/03/202308:00BWAlzamend Neuro Receives FDA “Study May Proceed” Letter for..
3/22/202308:00BWAlzamend Neuro Announces Completion of Clinical Portion of..
3/16/202308:00BWAlzamend Neuro Reports Third Fiscal Quarter Financial..
1/26/202308:00BWAlzamend Neuro to Present at Sequire Biotechnology..
1/04/202308:00BWAlzamend Neuro Partners With Biorasi to Conduct a..
12/28/202208:00BWAlzamend Neuro Partners With the Miller School of Medicine,..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |